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Abstract: Excessive cell death through apoptosis is at the origin of 
several pathologies, such as degenerative disorders, stroke or 
ischemia-reperfusion damage. In this context strategies to improve 
control inhibition of apoptosis and cell death are of interest and may 
represent a pharmacological opportunity for the treatment cell death-
related disorders. In this scenario new peptide-containing delivery 
systems (solids S1-P1 and S1-P2) are described based on 
mesoporous silica nanoparticles (MSNs) loaded with a dye and 
capped with the KKGDEVDKKARDEVDK (P1) peptide that contains 
two repeats of the DEVD target sequence which is selectively 
hydrolysed by the caspase-3 (C3) enzyme that plays a central role in 
the execution-phase of cell apoptosis. HeLa cells electroporated with 
S1-P1 are able to deliver the cargo in the presence of staurosporin 
(STS) which induces apoptosis with the consequent activation of the 
cytoplasmic C3 enzyme. Moreover the nanoparticles S1-P2, 
containing both a cell-penetrating TAT peptide and P1 also entered 
in HeLa cells and delivered the cargo preferentially in cells treated 
with the apoptosis inducer cisplatin. 
Recently the combination of new advances in 
nanotechnology and biomolecular chemistry has turned out in 
the design of new nanodevices able to develop innovative 
biologically related functions in areas such as bioengineering, 
biosensing and bionanotechnology.[1] In this context, 
mesoporous silica nanoparticles (MSNs) have proved to be 
excellent containers for storage and delivery due to their unique 
mesoporous structure and large loading capacity.[2] Moreover 
mesoporous silica can be easily functionalized, and this has 
allowed the design MSNs equipped with switchable 
molecular/supramolecular pore-capping ensembles able to be 
selectively opened with a number of different chemical, physical 
and biochemical stimuli.[3] This results in the design of stimuli-
responsive hybrid gated materials showing zero release yet able 
to deliver the cargo at-will.[4] 
In this scenario, the use of biomolecules has been widely 
used in the design of gated MSNs.[5] Among them, the 
combination of peptides as caps and enzymes as triggers offers 
great potential. In fact, although not as popular as other stimuli, 
the use of enzymes in gated materials is highly appealing as the 
use of tailor-made peptides and specific enzymes may induce 
remarkable selectivity to advanced gated devices for on-
command delivery in realistic biological environments. Although 
certain examples have been reported using esterases,[6] 
glycosidases,[7] peptidases,[8] reductases,[9] ureases{10] and 
DNases[11] this subfield in the area of gated nanochemistry has 
not been fully explored. Moreover the participation of enzymes in 
multiple biological steps makes this approach unique for the 
design of advanced delivery devices and there is still plenty of 
room in this field of research. In particular, and as far as we 
know, there are not MSNs specifically designed to be selectively 
opened in the presence of caspase enzymes. 
A number of gated materials have been designed for 
delivery of cytotoxics, with the main objective of reducing the 
secondary effects associated to classical chemotherapy due to 
the unspecific biodistribution of the drugs.[12] In contrast to this 
approach we have put our attention on the design of gated 
MSNs with the objective of decreasing unwanted cell death. 
Excessive cell death is at the origin of several pathologies, such 
as degenerative disorders, stroke or ischemia-reperfusion 
damage.[13] Therefore, controlled inhibition of cell death 
represents a pharmacological opportunity for the treatment of 
these disorders. Among the different types of cell death in this 
study we have focused on apoptosis,[14] a biological process in 
which the cell undergoes a series of biochemical and 
morphological changes that induce the destruction of the cell in 
a silent and ordered way. This process is initiated by a series of 
ligands that activate a family of cell death receptors located in 
the plasma membrane (extrinsic apoptosis) or after the induction 
of mitochondrial outer membrane permeabilization (MOMP) by 
internal cell death stimuli (intrinsic apoptosis).[15] No matter the 
origin, both pathways converge in the activation of a family of 
cysteine aspartyl proteases known as caspases. Once activated, 
these enzymes act as the executioner machinery of apoptosis 
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cleaving essential substrates of the cell, causing the dismantling 
of the cells.[16] In this scenario we have focused on caspase-3 
(C3). The C3 cleavage site on protein substrates is highly 
conserved and consists of a four amino acid target site (i.e. 
DEVD; Asp-Glu-Val-Asp) which is cleaved after the Asp 
residue.[17] This specificity allows C3 to be highly selective. 
A first approach to target apoptotic cells would be to 
develop selective-delivery carriers that are able to release their 
cargo in these particular cells. In this context, and taking into 
account our previous experience in the development of gated 
nanoparticles containing peptides as molecular caps,[18] we 
report herein the preparation of gated MSNs capable of 
selectively deliver their cargo in the presence of activated C3 
enzyme in cells (Figure 1A), once apoptosis has been induced. 
We selected mesoporous MCM-41 nanoparticles (ca. 100 nm) 
as inorganic scaffold which was synthesized according to 
reported procedures.[19] The nanoparticles were loaded with 
safranin O dye and the external silica surface was functionalized 
with 3-(azidopropyl)triethoxysilane (solid S1). The initial MCM-41 
and S1 support were subsequently characterized using standard 
techniques. The mesoporous structure of MCM-41 and S1 were 
confirmed by TEM and XRD studies (Figure 1B and 1C). The 
starting MCM-41 material and S1 showed a spherical shape of 
ca. 110 nm (see Supporting Information). Moreover the MCM-41 
calcined starting material showed a typical adsorption-
desorption isotherm of MSNs. The application of the BET model 
resulted in a value for the total specific surface of 1001.10 m2g-1 
and a pore volume of 0.79 cm3g-1. Besides a pore diameter of 
2.52 nm was calculated. In contrast, the N2 adsorption-
desorption isotherm of S1 was typical of mesoporous systems 
with partially filled mesopores and a significant decrease in the 
N2 volume adsorbed and in the surface area was found. In 
particular S1 showed a specific surface of 437.57 m
2g-1 and a 
pore volume of 0.31 cm3g-1 (see Supporting Information for 
further details).  
Finally S1 was capped with the peptidic sequence NH2-
KKGDEVDKKARDEVDK- alkyne, P1, (containing two repeats of 
the DEVD target sequence). P1 was attached to S1 by the 
copper(I)-catalyzed Huisgen azide/alkyne 1,3-dipolar 
cycloaddition “click” reaction,[20] which induces the formation of a 
1,2,3-triazole heterocycle upon reaction of the azide group (on 
the solid) and the triple bond (on P1). A scheme of the final 
material is depicted in Figure 1A. The P1-functionalized solid (S1-
P1) was isolated by centrifugation and washed to eliminate both 
residual dye and free peptide. TEM analysis confirmed that S1-
P1 retained the mesoporous structure (see Figure 1B). The 
safranine O and peptide contents in S1-P1 were determined by 
elemental analysis and thermogravimetric studies, and 
amounted to 0.130 and 0.034 mmol g-1 SiO2, respectively (see 
Supporting Information). 
To investigate the enzyme-responsive gating properties of 
S1-P1 in the presence of C3 0.5 mg of S1-P1 were suspended in 
PBS (10% glycerol, 1 mM DTT) and the suspension stirred at 
37ºC in the absence and in the presence of C3 enzyme. 
Uncapping and subsequent delivery of the dye was determined 
through the measurement of the fluorescence emission at 585 
nm (λex = 520 nm) of the safranine O dye released. The delivery 
profile is displayed in Figure 1D. It is show values of Safranin 
release at each time normalized against total release.  In the 
absence of caspase-3, solid S1-P1 showed a negligible dye 
release, indicating tight pore closure, whereas in the presence of 
C3 enzyme a clear cargo release was observed due to the 
hydrolysis of the peptide sequence P1. After 400 minutes, ca. 
80% of the total delivery was observed for S1-P1.  
Proved the specific cargo release in vitro, the proper 
aperture of the gated S1-P1 material was studied ex vitro using 
HeLa cells. It is well know that when nanoparticles of ca 100 nm 
are in contact with cells these are usually internalized by 
endocytosis reaching lysosomes. However in this case due to 
the cytoplasmic localization of C3 endocytosis of S1-P1 must be 
















































































































Figure 1. A) Schematic representation of the gated materials S1-P1 and S1-P2 
capped with peptides P1 and P2, red lines indicate the locations of caspase 
hydrolysis. B) From left to right, TEM images of calcined MCM-41, S1-P1 and 
S1-P2 showing the typical porosity associated to MCM-41 mesoporous matrix. 
C) Powder X-ray patterns of MCM-41 as synthesized, calcined MCM-41, S1, 
S1-P1 and S1-P2. D, E) In vitro release profiles of safranin O in the absence () 
and in the presence () of recombinant caspase-3 (C3) at 37°C and pH 7.2 for 
S1-P1 and S1-P2, respectively. 
 
Staurosporin, a nonspecific protein kinase inhibitor that 
induces apoptosis with the consequent activation of C3, was 
used for the activation of the caspase enzymes in HeLa cells.[21] 
Cleavage and aperture of the molecular gate of S1-P1 by C3 was 
assessed by confocal microscopy by means of safranin O 
associated fluorescence. For that purpose, cells were also 
stained with the DNA marker Hoechst 33342 and the cellular 
membrane marker Wheat Germ Agglutinin Alexa Fluor 647 
(WGA). Results are shown in Figure 2A. HeLa cells 
electroporated in the presence of S1-P1 in the absence of STS 
showed a poor cytoplasmic fluorescence associated to safranin 





O, whereas when similar experiments were carried out with cells 
treated with STS a clear safranin O fluorescence was observed. 
This difference was attributed to C3 activation and the 
subsequent hydrolysis of the P1 peptide containing the DEVD 
target sequence that resulted in cargo delivery. Moreover, in 
order to further prove the specific C3-mediated aperture of S1-P1, 
HeLa cells were electroporated with S1-P1 and treated with the 
C3 inhibitor Q-VD-OPh[22] for 24 hours previous the addition of 
STS. The objective was to block C3 activation. Under these 
conditions confocal microscopy images showed significant 
reduction of safranin O cytoplasmic signal, proving the major 
role of C3 in the aperture of the molecular gate (Figure 2A). 
Quantification of the cytoplasmic fluorescence associated to 
safranin O was determined for the different treatments and it is 
shown in Figure 2B. In agreement with confocal studies a 
significantly larger fluorescence was observed in cells 
electroporated with S1-P1 in the presence of STS (S1-P1+STS) 
when compared with S1-P1 and S1-P1+STS+Q-VD-OPh 
treatments. Besides to discard toxicity associated with S1-P1, cell 
viability in the absence of apoptotic stimulus at different 
nanoparticle concentrations was evaluated by WST-1 (Figure 
2C). No toxicity was found for S1-P1 up to concentrations of 100 
g mL-1. 
Figure 2. A) HeLa cells were electroporated in the presence of 100 g/mL S1-
P1 and incubated for 24 hours, previous the addition of STS 1.5 M when 
indicated for 4 hours. Inhibition of C3 by Q-VD-OPh 20 M was also performed 
24 hours prior the addition of STS. The cellular uptake of S1-P1 was followed 
by safranin O associated fluorescence (red) in the presence of DNA marker 
Hoechst 33342 (blue) and plasma membrane marker WGA Alexa Fluor®647 
(green). B) Quantification of the safranin O associated fluorescence intensity 
for the different treatments. Three independent experiments were developed 
obtaining similar results. Data are expressed as mean  s. Statistically 
significant differences were found among the different treatments when paired 
t Student test were applied, C) Cell viability analyzed by WST-1 at different 
nanoparticle concentrations. 
 
The experiments above demonstrated that MSNs were 
able to display cargo delivery in the presence of C3 enzyme via 
hydrolysis of the P1 capping peptide. However ex vivo 
experiments were performed by electroporation in order to 
increase the permeability of the cell membrane allowing S1-P1 
MSNs to be introduced in the cytosol where C3 enzyme exists. 
In this context we also considered the fact that synthetic 
peptides can be designed containing both, amino acid 
sequences recognized by target-enzyme and amino acid 
sequences in charge of cell entry-control. In this scenario a new 
peptidic sequence based on the original P1 was synthesized but 
this time adding to the N-terminal the sequence corresponding 
to the cell penetrating peptide TAT (peptide P2, see Figure 
1A).[23] The TAT peptide is known to facilitate cellular uptake of 
various molecular cargo from nanosize particles to small 
chemical molecules and large fragments of DNA.  
Figure 3. A) HeLa cells were treated with 100 g/mL S1-P2 and incubated for 4 
hours previous the addition of CDDP 50 M when indicated. After 24 hours of 
incubations confocal microscopy studies were performed. The cellular uptake 
of S1-P2 was followed by safranin O associated fluorescence (red) in the 
presence of DNA marker Hoechst 33342 (blue) and plasma membrane marker 
WGA Alexa Fluor®647 (green). Cytoplasmic safanin O associated 
fluorescence was observed in samples treated with S1-P2 and CDDP, but not 
in case of control samples treated only S1-P2. B) Quantification of the safranin 



















































independent experiments were developed obtaining similar results. Data are 
expressed as mean  s. Statistically significant differences were found among 
the different treatments when paired t Student test were applied, C) Cell 
viability analyzed by WST-1 at different nanoparticle concentrations. 
 
Solid S1-P2 was synthesized following a similar procedure to 
that used for the preparation of S1-P1 (see Figure 1A). The 
mesoporous structure in S1-P2 was confirmed by TEM and XRD 
studies (see Figure 1B and 1C). The safranin O and peptide 
contents in S1-P2 were determined by elemental analysis and 
thermogravimetric studies, and amounted to 0.205 and 0.016 
mmol g-1 SiO2, respectively (see Supporting Information). S1-P2 
nanoparticles were suspended in PBS (10% glycerol, 1 mM 
DTT) at 37ºC in the absence and in the presence of C3 enzyme. 
The delivery kinetics profile is displayed in Figure 1E. S1-P2 
showed a poor cargo delivery in the absence of recombinant C3 
whereas a clear cargo release was observed in the presence of 
this enzyme. Moreover studies in HeLa cells were performed 
following similar procedures than those used for S1-P1 but 
without the use of electroporation. Besides in this case cisplatin 
(CDDP), which causes DNA crosslinks, was employed as 
apoptosis inducer to activate C3.[24] In a typical experiment HeLa 
cells were seeded, and 24 hours later, were treated with S1-P2 
for 6 hours and then CDDP was added when indicated. 24 hours 
later, cells were stained with the DNA marker Hoechst 33342 
and the cellular membrane marker WGA and cells were studied 
by confocal microscopy. Appearance of cytoplasmic associated 
safranin O fluorescence can be observed in case of the cells 
treated with S1-P2 in the presence of CDDP (Figure 3A). By 
contrast, a very poor safranin O signal was detected in S1-P2 
treated cells in the absence of the apoptosis inducer. 
Subsequent quantification of safranin O cytoplasmic associated 
fluorescence showed a significant emission increase in cells 
treated with CDDP when compared to control cells (Figure 3B). 
Besides to discard toxicity associated with S1-P2 cell viability in 
the absence of apoptotic stimulus at different nanoparticle 
concentrations was evaluated by WST-1 (Figure 3C). No 
important toxicity was found for S1-P2 nanoparticles up to 
concentrations of 100 g mL-1.  
In summary, we have shown here that it is possible to use 
capping peptide sequences on mesoporous silica supports in 
order to develop nanodevices showing nearly “zero” release yet 
specifically opened in the presence of the targeted proteolytic 
enzyme C3 in cells. HeLa cells electroporated with S1-P1 
showed a poor cytoplasmic fluorescence associated to safranin 
O while a clear cargo release was observed in the presence of 
the apoptosis inducer STS. Moreover the nanoparticles S1-P2, 
containing both a cell-penetrating TAT peptide and P1, entered 
in HeLa cells and delivered the cargo preferentially in cells 
treated with the apoptosis inducer cisplatin. These can be 
considered preliminary results towards adopting new therapeutic 
strategies to inhibit cell death due to apoptosis. Based in the fact 
that the field of peptide-protease pair is well-known and offers 
advanced opportunities for on command delivery protocols, we 
believe that the synthetic strategy followed herein, which 
combines the use of mesoporous nanoparticles with highly 
specific targeting peptides, can have biomedical relevance to 




We thank the Spanish Government (Project MAT2012-38429-
C04 and SAF2010-15512) and the Generalitat Valenciana 
(PROMETEOII/2014/061) for support. C.T. is grateful to the 
Spanish Ministry of Science and Innovation for her PhD 
fellowship. L.M. thanks the Generalitat Valenciana (VALI+D 
program), Nice city council (“Aides Individuelles aux Jeunes 
Chercheurs - 2011”) and Fondation de la Recherche Médicale 
for her post-doctoral contracts. C.C. thanks the 
GeneralitatValenciana for their post-doctoral contract VALI+D. 
We thank the confocal microscopy service, Alberto Hernández 
from CIPF confocal microscopy service for their technical 
support. 
Keywords: caspase 3 • controlled release • peptides • gated 
mesoporous materials • nanoparticles 
[1] a) K. Ariga, Q. M. Ji, M. J. McShane, Y. M. Lvov, A. Vinu, J. P. Hill, 
Chem. Mat. 2012, 24, 728-737. b) L. Treccani, T. Y. Klein, F. Meder, K. 
Pardun, K. Rezwan, Acta Biomater. 2013, 9, 7115-7150. 
[2] F. Hoffmann, M. Cornelius, J. Morell, M. Froba, Angew. Chem. Int. Edit. 
2006, 45, 3216-3251. 
[3] a) E. Aznar, R. Martínez-Máñez, F. Sancenón, Exp. Opin. Drug Deliv. 
Rev. 2009, 6, 643-655. b) C. Coll, A. Bernardos, R. Martínez-Máñez, F. 
Sancenón, Acc. Chem. Res. 2013, 46, 339-349. 
[4] a) P. Yang, S. Gai, J. Lin, Chem. Soc. Rev. 2012, 41, 3679-3698. b) Z. 
Li, J. C. Barnes, A. Bosoy, J. F. Stoddart, J. I. Zink, Chem. Soc. Rev. 
2012, 41, 2590-2605. c) B. W. Trewyn, I. I. Slowing, S. Giri, H. -T. Chen, 
V. S. –Y. Lin, Acc. Chem. Res. 2007, 40, 846-853. 
[5] a) D. Tarn, C. E. Ashley, M. Xue, E. C. Carnes, J. I. Zink, C. J. Brinker, 
Acc. Chem. Res. 2013, 46, 792-801. b) C. –H. Lu, B. Willner, I. Willner, 
ACS Nano 2013, 7, 8320-8332. c) Q. He, J. Shi, J. Mater. Chem. 2011, 
21, 5845-5855. 
[6] a) K. Patel, S. Angelos, W. R. Dichtel, A. Coskun, Y. W. Yang, J. I. Zink, 
J. F. Stoddart, J. Am. Chem. Soc. 2008, 130, 2382-2383. b) Y. –L. Sun, 
Y. Zhou, Q. –L. Li, Y. –W. Yang, Chem.Commun. 2013, 49, 9033-9035. 
c) A. Bernardos, L. Mondragón, I. Javakhishvili, N. Mas, C. de la Torre, 
R. Martínez-Máñez, F. Sancenón, J. M: Barat, S. Hvilsted, M. Orzáez, E. 
Pérez-Payá, P.  Amorós, Chem. Eur. J. 2012, 18, 13068-13078.  
[7] a) A. Bernardos, E. Aznar, M. D. Marcos, R. Martínez-Máñez, F. 
Sancenón, J. Soto, J. M: Barat, P. Amorós, Angew. Chem. Int. Ed. 2009, 
48, 5884-5887. b) A. Agostini, L. Mondragón, A. Bernardos, R. 
Martínez-Máñez, M. D. Marcos, F. Sancenón, J. Soto, A. Costero, C. 
Manguán-García, R. Perona, M. Moreno-Torres, R. Aparicio-Sanchís, J. 
R. Murguía, Angew. Chem. Int. Ed. 2012, 51, 10556-10560.  c) M. L. 
Yin, E. G. Ju, Z. W. Chen, Z. H.  Li, J. S. Ren, X. G. Qu, Chem. Eur. J. 
2014, 20, 14012-14017. 
[8] a) A. Schlossbauer, J. Kecht, T. Bein, Angew. Chem. Int. Ed. 2009, 48, 
3092-3095. b) P. D. Thornton, A. Heise, J. Am. Chem. Soc. 2010, 132, 
2024-2028. c) X. J. Yang, F. Pu, C. E. Chen, J. S. Ren, X. G. Qu, 
Chem. Commun. 2012, 48, 11133-11135. 
[9] a) N. Mas, A. Agostini, L. Mondragón, A. Bernardos, F. Sancenón, M. D. 
Marcos, R. Martínez-Máñez, A. M. Costero, S. Gil, M. Merino-Sanjuan, 
P. Amorós, M. Orzáez, E. Pérez-Payá, Chem. Eur. J. 2013, 19, 1346-
1356. b) X. Li, T. Tang, Y. Zhou, Y. Zhang, Y. Sun, Micropor. Mesopor. 
Mater. 2014, 184, 83-89. 
[10] A. Agostini, L. Mondragón, C. Coll, E. Aznar, M. D. Marcos, R. 
Martínez-Máñez, F. Sancenón, J. Soto, E. Pérez-Payá, P. Amorós, 
ChemistryOpen 2012, 1, 17-20. 
[11] a) Y. F. Zhu, W. J. Meng, N. Hanagata, Dalton Trans. 2011, 40, 10203-
10208. b) G. Zhang, M. Yang, D. Cai, K. Zheng, X. Zhang, L. Wu, Z. Wu, 
ACS Appl. Mater. Inter. 2014, 6, 8042-8047. 
[12] L. M. Bimbo, L. Peltonen, J. Hirvonen, H. A. Santos, Curr. Drug Metab. 
2012, 13, 1068-1086. 
[13] D. R. Green, G. Kroemer, J. Clin. Invest. 2005, 115, 2610-2617. 
[14] G. Kroemer, L. Galluzzi, P. Vandenabeele, J. Abrams, E. S. Alnemri, E. 
H. Baehrecke, M. V. Blagosklonny, W. S. El-Deiry, P. Golstein, D. R. 





Green, M. Hengartner, R. A. Knight, S. Kumar, S. A. Lipton, W. Malorni, 
G. Nunez, M. E. Peter, J. Tschopp, J. Yuan, M. Piacentini, B. 
Zhivotovsky, G. Melino, Cell Death Differ. 2009, 16, 3-11. 
[15] a) A. Jourdain, J. -C. Martinou, Int. J. Biochem. Cell Biol. 2009, 41, 
1884-1889. B) M. R. Sprick, H. Walczak, BBA-Mol. Cell Res. 2004, 
1644, 125-132. 
[16] M. Poreba, A. Strozyk, G. S. Salvesen, M. Drag, Cold Spring Harb. 
Perspect. Biol. 2013, 5, a008680. 
[17] a) J. -B. Denault, G. S. Salvesen, Methods Mol. Biol.  2008, 414, 191-
220. b) C. Pop, G. S. Salvesen, F. L. Scott, in Programmed Cell Death, 
the Biology and Therapeutic Implications of Cell Death, Part B 2008, 
446, 351-367. 
[18] a) C. Coll, L. Mondragon, R. Martinez-Manez, F. Sancenon, M. D. 
Marcos, J. Soto, P. Amoros, E. Perez-Paya, Angew. Chem. Int. Edit. 
2011, 50, 2138-2140. b) C. de la Torre, L. Mondragón, C. Coll, F. 
Sancenón, M. D. Marcos, R. Martínez-Máñez, P. Amorós, E. Pérez-
Payá, M. Orzáez, Chem. Eur. J. 2014, 20, 15309-15314. c) C. de la 
Torre, A. Agostini, L. Mondragon, M. Orzaez, F. Sancenon, R. Martinez-
Manez, M. D. Marcos, P. Amoros, E. Perez-Paya, Chem. Commun. 
2014, 50, 3184-3186. d) L. Mondragon, N. Mas, V. Ferragud, C. de la 
Torre, A. Agostini, R. Martinez-Manez, F. Sancenon, P. Amoros, E. 
Perez-Paya, M. Orzaez, Chem. Eur. J. 2014, 20, 5271-5281. e) A. 
Agostini, L. Mondragón, C. Coll, E. Aznar, M. D. Marcos, R. Martínez-
Máñez, F. Sancenón, J. Soto, E. Pérez-Payá, P. Amorós, 
ChemistryOpen 2012, 1, 17-20. 
[19] a) C. T. Kresge, M. E. Leonowicz, W. J. Roth, J. C. Vartuli, J. S. Beck, 
Nature 1992, 359, 710-712. b) N. K. Mal, M. Fujiwara, Y. Tanaka, 
Nature 2003, 421, 350-353.  
[20] a) V. V Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless, Angew. 
Chem. Int. Ed. 2002, 41, 2596-2599. b) C. W. Tornoe, C. Christensen, 
M. Meldal, J. Org. Chem. 2002, 67, 3057-3064. c) H. C. Kolb, M. G. 
Finn, K. B. Sharpless, Angew. Chem. Int. Ed. 2001, 40, 2004-2021.  
[21] M. Andersson, J. Sjostrand, A. Petersen, A. K. S. Honarvar, J. O. 
Karlsson, Invest. Ophthalmol. Vis. Sci. 2000, 41, 2623-2632. 
[22] T. L. Brown, in Cell Volume and Signaling 2004, 559, 293-300. 
[23] a) H. Brooks, B. Lebleu, E. Vives, Advanced Drug Deliver. Rev. 2005, 
57, 559-577. b) S. M. Farkhani, A. Valizadeh, H. Karami, S. 
Mohammadi, N. Sohrabi, F. Badrzadeh, Peptides 2014, 57, 78-94. c) M. 
Orzaez, L. Mondragon, I. Marzo, G. Sanclimens, A. Messeguer, E. 
Perez-Paya, M. J. Vicent, Peptides 2007, 28, 958-968. 
[24] L. Mondragon, L. Galluzzi, S. Mouhamad, M. Orzaez, J. M. Vicencio, I. 
Vitale, A. Moure, A. Messeguer, E. Perez-Paya, G. Kroemer, Apoptosis 











































S1-P1 and S1-P2 
nanoparticles capped 
with a peptide 
sequence recognized 
and hydrolyzed by 
caspase 3 enzyme 
were synthesized and 
characterized. In vitro 
and ex vitro studies of 
both materials proved 
the caspase 3 induced 
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